Cellular Biomedicine Group, Inc. Information Request Form

Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Cellular Biomedicine Group, Inc. (“Cellular Biomedicine” or the “Company”) (NASDAQ: CBMG) to a consortium that includes members of Cellular Biomedicine management and several entities that collectively hold approximately 51.5% of the outstanding Cellular Biomedicine shares. Under the terms of the merger, Cellular Biomedicine stockholders will receive $19.75 in cash for each outstanding share of common stock held immediately prior to the effective time of the merger.

The Cellular Biomedicine merger investigation concerns whether the Board of Cellular Biomedicine has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.